Cannabis exposure during pregnancy and perinatal outcomes: A cohort study
Acta Obstetricia et Gynecologica Scandinavica · 2024-06 · 103 (6) · 1083-1091
DOI: 10.1111/aogs.14818 ↗At a glance
Kohortenstudie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2024-03-19. Written by Maia Brik and 8 co-authors. Institution: Obstetrics Department, Maternal-Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Major MEDLINE topics: Infant, Small for Gestational Age, Pregnancy Outcome, Premature Birth, Propensity Score. Cited 7 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Introduction
Cannabis potency and its use during pregnancy have increased in the last decade. The aim of this study was to investigate the impact of antenatal cannabis use on fetal growth, preterm birth and other perinatal outcomes. Material and methods A propensity score‐matched analysis was performed in women with singleton pregnancies attending a tertiary care site in Barcelona. Women in the cannabis group were selected based on the results of a detection test. Primary outcomes were small for gestational age at birth (SGA), low birthweight and preterm birth. Secondary outcomes were other biometric parameters (neonatal length and head circumference), respiratory distress, admission to the neonatal intensive care unit and breastfeeding at discharge. A second propensity score‐matched analysis excluding other confounders (use of other recreational drugs and discontinuation of cannabis use during pregnancy) was performed.
Results
Antenatal cannabis was associated with a higher odds ratio of SGA (OR 3.60, 95% CI: 1.68–7.69), low birthweight (OR 3.94, 95% CI: 2.17–7.13), preterm birth at 37 weeks (OR 2.07, 95% CI: 1.12–3.84) and 32 weeks of gestation (OR 4.13, 95% CI: 1.06–16.11), admission to the neonatal intensive care unit (OR 1.95, 95% CI: 1.03–3.71), respiratory distress (OR 2.77, 95% CI: 1.26–6.34), and lower breastfeeding rates at discharge (OR 0.10, 95% CI: 0.05–0.18). When excluding other confounders, no significant association between antenatal cannabis use and SGA was found.
Conclusions
Antenatal cannabis use increases the risk of SGA, low birthweight, preterm birth and other adverse perinatal outcomes. However, when isolating the impact of cannabis use by excluding women who use other recreational drugs and those who discontinue cannabis during pregnancy, no significant association between antenatal cannabis use and SGA birth was found.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Obstetrics Department, Maternal-Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Mental Health Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Statistics and Bioinformatics Unit (UEB) Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
ORCID profiles: Maia Brik, Nerea Maiz
Cite
APA
Brik, M., Sandonis, M., Hernández-Fleury, A., Gil, J., Mota, M., Barranco, F. J., Garcia, I., Maiz, N., & Carreras, E. (2024). Cannabis exposure during pregnancy and perinatal outcomes: A cohort study. Acta Obstetricia et Gynecologica Scandinavica, 103(6), 1083-1091. https://doi.org/10.1111/aogs.14818
Vancouver
Brik M, Sandonis M, Hernández-Fleury A, Gil J, Mota M, Barranco FJ, et al. Cannabis exposure during pregnancy and perinatal outcomes: A cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2024;103(6):1083-1091. doi:10.1111/aogs.14818
BibTeX
@article{Brik2024,
author = {Brik, Maia and Sandonis, Miguel and Hernández-Fleury, Alina and Gil, Judit and Mota, Miriam and Barranco, Francisco José and Garcia, Itziar and Maiz, Nerea and Carreras, Elena},
title = {Cannabis exposure during pregnancy and perinatal outcomes: A cohort study},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2024},
volume = {103},
number = {6},
pages = {1083--1091},
doi = {10.1111/aogs.14818}
}
EUVIMED